To highlight the safety and efficacy of tocilizumab (TCZ) in Graves’ ophthalmopathy (GO) combined with ocular myasthenia gravis (OMG) patients refractory to steroids and cholinesterase inhibitor (CEI).
You are here: Home / News / Tocilizumab for the management of corticosteroid-resistant GO combined with OMG: a case series
Leave a Reply